Literature DB >> 12804527

The complement system as a therapeutic target in autoimmunity.

V Michael Holers1.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 12804527     DOI： 10.1016/s1521-6616(03)00034-2

Source DB:  PubMed          Journal:  Clin Immunol        ISSN： 1521-6616            Impact factor:   3.969


× No keyword cloud information.
  36 in total

1.  Matrix metalloproteinase activity creates pro-angiogenic environment in primary human retinal pigment epithelial cells exposed to complement.

Authors:  Mausumi Bandyopadhyay; Bärbel Rohrer
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-04-18       Impact factor: 4.799

Review 2.  Progress in defining the molecular biology of age related macular degeneration.

Authors:  Andrew Lotery; Dorothy Trump
Journal:  Hum Genet       Date:  2007-07-21       Impact factor: 4.132

Review 3.  Molecular structure and expression of anthropic, ovine, and murine forms of complement receptor type 2.

Authors:  Dong Liu; Jian-Ying Zhu; Zhong-Xiang Niu
Journal:  Clin Vaccine Immunol       Date:  2008-04-09

4.  Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases.

Authors:  Masha Fridkis-Hareli; Michael Storek; Istvan Mazsaroff; Antonio M Risitano; Ante S Lundberg; Christopher J Horvath; V Michael Holers
Journal:  Blood       Date:  2011-08-22       Impact factor: 22.113

5.  The Relationship of Longitudinal Levels of Complement Bb During Pregnancy with Preeclampsia.

Authors:  Anne M Lynch; Brandie D Wagner; Patricia C Giclas; Nancy A West; Ronald S Gibbs; V Michael Holers
Journal:  Am J Reprod Immunol       Date:  2015-10-29       Impact factor: 3.886

6.  Sublytic membrane-attack-complex (MAC) activation alters regulated rather than constitutive vascular endothelial growth factor (VEGF) secretion in retinal pigment epithelium monolayers.

Authors:  Kannan Kunchithapautham; Bärbel Rohrer
Journal:  J Biol Chem       Date:  2011-05-12       Impact factor: 5.157

7.  Fragment Bb in amniotic fluid: evidence for complement activation by the alternative pathway in women with intra-amniotic infection/inflammation.

Authors:  Edi Vaisbuch; Roberto Romero; Offer Erez; Shali Mazaki-Tovi; Juan Pedro Kusanovic; Kusanovic Juan Pedro; Eleazar Soto; Francesca Gotsch; Zhong Dong; Tinnakorn Chaiworapongsa; Sun Kwon Kim; Pooja Mittal; Percy Pacora; Lami Yeo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2009-10

Review 8.  Complement and autoimmunity.

Authors:  Eleonora Ballanti; Carlo Perricone; Elisabetta Greco; Marta Ballanti; Gioia Di Muzio; Maria Sole Chimenti; Roberto Perricone
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

9.  A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma.

Authors:  Emilian Racila; Brian K Link; Wen-Kai Weng; Thomas E Witzig; Stephen Ansell; Matthew J Maurer; Jian Huang; Christopher Dahle; Ahmad Halwani; Ronald Levy; George J Weiner
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

10.  B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis.

Authors:  Joseph M Tuscano; Jacob Sands
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.